{
  "docId": "019de075-992f-724e-90ab-5f77d740e3ca",
  "docSlug": "2f355093e0d1610f6a0dd544c49160f7",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 33,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "other",
  "function": "cite_precedent",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide outlines two main pillars of the collaboration: targeted alpha therapies and combination therapies.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-992f-724e-90ab-5f77d740e3ca/19",
  "deckHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca",
  "deckJsonHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca.json",
  "deckAnchorHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.94,
        "x": 0.03,
        "y": 0.8
      },
      "kind": "callout",
      "text": "Collaboration combines AstraZeneca’s ADC and oncology expertise with Fusion’s TAT discovery, development and manufacturing platform",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "581c7ec3-d8de-45f4-8504-4af568df5fde",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.34,
        "x": 0.33,
        "y": 0.15
      },
      "kind": "image",
      "text": "Fusion + AstraZeneca",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18d931a6-e990-40aa-991d-310f60dd783f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.03,
        "y": 0.034
      },
      "kind": "list",
      "text": "1. Three Novel Targeted Alpha Therapies: Co-fund, Co-develop, Option to co-commercialize in U.S.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "159ae4b6-f460-4566-a677-b74653dcd782",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.52,
        "y": 0.034
      },
      "kind": "list",
      "text": "2. Up to 5 Combination Therapies with TATs: DNA Damage Response Inhibitors (DDRis), Immuno-oncology agents, AZ solely funds unless Fusion opts-in",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1adcb8a1-9914-4845-b2f4-b4011398a8c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Collaboration Agreement with AstraZeneca",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "197aa68a-038d-4f19-a17e-799dc0741244",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "9b9cb7be-a817-4a07-91f2-8feb35e22a9e",
      "evidence": "Collaboration combines AstraZeneca’s ADC and oncology expertise with Fusion’s TAT discovery, development and manufacturing platform",
      "confidence": 0.7
    },
    {
      "name": "Call to action",
      "slug": "call-to-action",
      "agent": null,
      "layer": "slide",
      "matchId": "1cfe4cef-4bdd-4235-aeb2-42aafabcdb47",
      "evidence": "Collaboration Agreement with AstraZeneca",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}